Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study

Table 3 Kaplan-Meier estimated survival over 5 years

Group	1-year survival (%)	3-year survival (%)	5-year survival (%)	Median survival (95%CI)	Log-rank P value
Survival without Rebleeding
Group A (DAA-treated)	95	85	75	4.5 years (4.2-4.7)	< 0.001a
Group B (non-DAA-treated)	80	60	45	3.2 years (2.7-3.7)
Overall survival
Group A (DAA-treated)	98	92	88	Not reached	0.012a
Group B (non-DAA-treated)	90	75	65	4.8 years (4.2-5.4)

^aP < 0.05.

The log-rank test confirmed significant differences in survival without rebleeding and overall survival between groups. DAA: Direct-acting antiviral.